Jan Willems

646 citations
16 papers · 545 indexed · h-index 11
Topics
Immune Cell Function and Interaction (5 papers)Vascular Tumors and Angiosarcomas (3 papers)Cancer Immunotherapy and Biomarkers (3 papers)
Partner nations
SwedenFinland

In The Last Decade

Jan Willems

16 papers receiving 519 citations

Peers

Jan Willems
Comparison fields: 5 of 57
  • Oncology 192
  • Immunology 184
  • Pulmonary and Respiratory Medicine 160
  • Rheumatology 90
  • Pathology and Forensic Medicine 85
Replace H Pickartz with:
H Pickartz Germany
Hossein Hemmatazad Switzerland
N Horschowski France
Dai Ikebe Japan
Aldo Mombello Italy
Soo Kee Min South Korea
Luis Buelta Spain
Daniele Remotti Italy
Ikuko Hayakawa Japan
Ali Shahsafaei United States
Jan Willems relative to H Pickartz Germany H Pickartz's profile →
Citations per field
00.5×1.5×2.3×
H Pickartz · 1×
Citations per year

Countries citing papers authored by Jan Willems

Since Specialization
Citations

This map shows the geographic impact of Jan Willems's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Willems with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Willems more than expected).

Fields of papers citing papers by Jan Willems

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Willems. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Willems. The network helps show where Jan Willems may publish in the future.

Co-authorship network of co-authors of Jan Willems

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Willems. A scholar is included among the top collaborators of Jan Willems based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Willems. Jan Willems is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
#WorkIndexed citations
1 71
2
Regulation of cadherin functions by synthetic peptides containing an H-A-V sequence
2
3 37
4 27
5 9
6 15
7 7
8 104
9 10
10 39
11 21
12 74
13 5
14 41
15 49
16 34

About Jan Willems

Jan Willems is a scholar working on Oncology, Immunology and Ophthalmology, having authored 16 papers that have together received 545 indexed citations. Recurring topics across this work include Immune Cell Function and Interaction (5 papers), Vascular Tumors and Angiosarcomas (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). The work is most often cited by research in Immunology (184 citations), Oncology (192 citations) and Rheumatology (90 citations). Jan Willems has collaborated with scholars based in Sweden and Finland. Frequent co-authors include Andris Kreicbergs, Eva Klein, Henrik C. F. Bauer, Bernhard Tribukait, Lennart Angervall, Lars‐Gunnar Kindblom, BK Kim, Inti Peredo, Abiel Orrego and Cecilia Söderberg‐Nauclér. Their work appears in journals such as Cancer, International Journal of Cancer and World Journal of Surgery.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026